Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Tamar Rachmilewitz Minei"'
Autor:
Michael J. Birrer, Rebecca C. Arend, McKenzie E. Foxall, Hannah M. Beer, Jaclyn A. Wall, Susana M. Campos, Suzanne Berlin, Yael C Cohen, Tamar Rachmilewitz Minei, Richard T. Penson, Dror Harats
Publikováno v:
Gynecologic Oncology. 157:578-584
Objective Report final results of a phase I/II study of VB-111, a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response, in combination with paclitaxel in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45936967b82485c6ebc8bc4a29520c75
https://doi.org/10.1016/j.ygyno.2020.02.034
https://doi.org/10.1016/j.ygyno.2020.02.034
Autor:
Jian Campian, Andrew Brenner, Patrick Y. Wen, Shifra Fain Shmueli, John de Groot, Tamar Rachmilewitz Minei, Laurence S. Freedman, Noa Lowenton-Spier, Leor Zach, Nicholas Butowski, Timothy F. Cloughesy, Benjamin M. Ellingson, Yael C Cohen
Publikováno v:
Neuro-Oncology. 22:705-717
BackgroundOfranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0a1a4a7731cf802c2985f90ac93b982
https://doi.org/10.1093/neuonc/noz232
https://doi.org/10.1093/neuonc/noz232
Autor:
Chencai Wang, Kunal S. Patel, Jian Campian, Timothy F. Cloughesy, Shan Rizvi, Patrick Y. Wen, Noa Lowenton-Spier, Leor Zach, Andrew Brenner, Tamar Rachmilewitz Minei, Yael C Cohen, Nicholas Butowski, Benjamin M. Ellingson, Catalina Raymond, John de Groot, Jacob Schlossman, Shifra Fain Shmueli
Publikováno v:
Neuro-oncology advances, vol 3, iss 1
Neuro-oncology Advances
Neuro-oncology Advances
Background Evidence from single and multicenter phase II trials have suggested diffusion MRI is a predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF therapy. The current study confirms these find
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a33780ff3ae4736d8bd0e2fe95b2f023
https://escholarship.org/uc/item/05g831w8
https://escholarship.org/uc/item/05g831w8
Autor:
Richard T. Penson, Rebecca Christian Arend, Angeles Alvarez Secord, Antonio Casado Herraez, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Shifra Fain Shmueli, Bradley J. Monk
Publikováno v:
Journal of Clinical Oncology. 40:TPS5606-TPS5606
TPS5606 Background: Ofranergene obadenovec (Ofra-vec, VB-111) is an anti-cancer gene based immune activator and targeted vascular disruptor. The dual mechanism of action triggers a broad antiangiogenic effect and induces of a tumor directed immune re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec184efe3077eb4aff684c2f9841f4fe
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5606
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5606
Autor:
Patrick Y. Wen, Andrew J. Brenner, Nicholas A. Butowski, Tamar Rachmilewitz Minei, Dror Harats, Timothy Francis Cloughesy
Publikováno v:
Journal of Clinical Oncology. 40:TPS2075-TPS2075
TPS2075 Background: Ofranergene obadenovec (ofra-vec, VB-111) is an anti-cancer gene based immune activator and targeted vascular disruptor. The dual mechanism of action triggers a broad antiangiogenic effect and induces of a tumor directed immune re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ec74f8958a5972530d011308923564d
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2075
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2075
Autor:
Angeles Alvarez Secord, Michal Lavi, Bradley J. Monk, Austin Miller, Jonathan A. Ledermann, Kathleen N. Moore, Richard T. Penson, Tamar Rachmilewitz Minei, Laurence S. Freedman, Thomas J. Herzog, Krishnansu S. Tewari, Shifra Fain Shmueli, Ronnie Shapira-Frommer, Rebecca C. Arend
Publikováno v:
Gynecologic oncology. 161(2)
Objective Report the results from a preplanned interim analysis of a phase III, double blind, randomized controlled study of ofranergene obadenovec (VB-111), a targeted anti-cancer gene therapy, in combination with paclitaxel in patients with platinu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed85c5f2cc28defe787ca5e61538ecfd
https://pubmed.ncbi.nlm.nih.gov/33637348
https://pubmed.ncbi.nlm.nih.gov/33637348
Autor:
Shan Rizvi, Kunal S. Patel, Jian Campian, Leor Zach, Catalina Raymond, Chencai Wang, Timothy F. Cloughesy, Jacob Schlossman, Nicholas Butowski, Yael Cohen, Noa Lowenton-Spier, Andrew Brenner, John de Groot, Benjamin M. Ellingson, Tamar Rachmilewitz Minei, Shifra Fain-Shmueli, Patrick Y. Wen
Publikováno v:
Neuro Oncol
BACKGROUND Evidence from independent single center as well as multicenter phase II trials have suggested diffusion MRI is a strong predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF monotherapy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29489d2f1ae5aad4638947e3c7699b56
https://europepmc.org/articles/PMC7651187/
https://europepmc.org/articles/PMC7651187/
Autor:
Timothy F. Cloughesy, Laurence S. Freedman, Felix Bokstein, Benjamin M. Ellingson, Andrew Brenner, Katherine B. Peters, Naamit Sher, Eyal Breitbart, Shlomit Yust-Katz, Patrick Y. Wen, Itzhak Mendel, Bernice Oberman, Idit Peretz, Tamar Rachmilewitz Minei, Niva Yakov, James J. Vredenburgh, Deborah T. Blumenthal, Yael C Cohen, Noa Lowenton-Spier
Publikováno v:
Neuro-oncology, vol 22, iss 5
Neuro-Oncology
Neuro-Oncology
Background VB-111 is a non-replicating adenovirus carrying a Fas-chimera transgene, leading to targeted apoptosis of tumor vascular endothelium and induction of a tumor-specific immune response. This phase I/II study evaluated the safety, tolerabilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46c0464ac87173392444905e4373dc6
https://escholarship.org/uc/item/269665k9
https://escholarship.org/uc/item/269665k9
Autor:
Rebecca Christian Arend, Bradley J. Monk, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, Ronnie Shapira-Frommer, Krishnansu Sujata Tewari, Tamar Rachmilewitz Minei, Dror Harats, Richard T. Penson
Publikováno v:
Journal of Clinical Oncology. 39:TPS5599-TPS5599
TPS5599 Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism of action that includes a broad antiangiogenic effect and induction of a tumor directed immune response. A phase II trial in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1213359f079769cf15b23a5313117f5e
https://doi.org/10.1200/jco.2021.39.15_suppl.tps5599
https://doi.org/10.1200/jco.2021.39.15_suppl.tps5599
Autor:
Bradley J. Monk, Richard T. Penson, Kathleen N. Moore, Robert A. Burger, Marilyn Huang, Thomas J. Herzog, Rebecca C. Arend, Krishnansu S. Tewari, Amnon Amit, Angeles Alvarez Secord, Dror Harats, Tamar Rachmilewitz Minei, Roni Shapira, Jonathan A. Ledermann
Publikováno v:
Journal of Clinical Oncology. 38:TPS6097-TPS6097
TPS6097 Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism: a broad antiangiogenic effect and induction of a tumor directed viral immune response. In a phase II trial in platinum resistant ovarian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::580f47a67c39536254c2c794acc9eee0
https://doi.org/10.1200/jco.2020.38.15_suppl.tps6097
https://doi.org/10.1200/jco.2020.38.15_suppl.tps6097